Press Releases Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange Other stock markets 11:30:00 26/06/2024 am IST			5-day change	1st Jan Change
6,251 ^JPY	+0.43%		+3.02%	-8.05%

25/06	Japanese Shares Close Higher as Officials Address Yen Volatility Concerns	MT
25/06	Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shionogi & Co., Ltd. - Option Agreement with Cilcare for Development Compounds Addressing Hearing Loss	07/06	AQ
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats	05/06	AQ
Shionogi & Co., Ltd. - Launch of the Gram-negative Bacterial Infection Treatment FETROJA 1g, in Taiwan	29/05	AQ
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13/05	AQ
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09/05	AQ
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04	AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04	AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04	AQ
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04	AQ
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03	AQ
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06/03	AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06/03	AQ
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05/03	AQ
Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition	04/03	AQ
Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University	04/03	AQ
Shionogi Announces appointment of Auditors, Corporate officers, Corporate Reorganization and Personnel Reassignment	29/02	AQ
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02	AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02	AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02	AQ
Shionogi - Announcement of the Strategic Business Partnership Agreement for Diagnosis Support AI Program in Dementia and Depression between FRONTEO and Shionogi	15/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Press Releases

Filters